<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>empagliflozin &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/empagliflozin/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 08 Oct 2026 11:58:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>empagliflozin &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Diabetes Drugs May Ease Pulmonary Hypertension by Taming Activin A Signaling</title>
		<link>https://bioengineer.org/diabetes-drugs-may-ease-pulmonary-hypertension-by-taming-activin-a-signaling/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 11:58:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[activin A]]></category>
		<category><![CDATA[autophagy]]></category>
		<category><![CDATA[BMPR2]]></category>
		<category><![CDATA[dapagliflozin]]></category>
		<category><![CDATA[empagliflozin]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[ischemic cardiomyopathy]]></category>
		<category><![CDATA[miR-1306-5p]]></category>
		<category><![CDATA[pulmonary hypertension]]></category>
		<category><![CDATA[right ventricle]]></category>
		<category><![CDATA[SGLT2 inhibitors]]></category>
		<category><![CDATA[TGF-beta signaling]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=407346</guid>

					<description><![CDATA[A new study links SGLT2 inhibitor therapy with reduced circulating activin A, improved right-heart function, and modulation of BMP/activin signaling in ischemic heart failure patients at high risk of pulmonary hypertension.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">407346</post-id>	</item>
	</channel>
</rss>
